Your institution may have access to this item. Find your institution then sign in to continue.
Title
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil<sup>“</sup>) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
Authors
M. E. R. O’Brien; M. Inbar; R. Rosso; E. Grischke; A. Santoro; R. Catane; D. G. Kieback; P. Tomczak; S. P. Ackland; F. Orlandi; L. Mellars; L. Alland; C. Tendler